|
Lung diseases
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Lung disease in STING N153S mice developed independently of cGAS, IRF3/IRF7, and IFNAR1.
|
30772497 |
2019 |
|
Tuberculosis
|
0.040 |
Biomarker
|
disease |
BEFREE |
Cyclic GMP-AMP Synthase Is an Innate Immune DNA Sensor for Mycobacterium tuberculosis.
|
26048137 |
2015 |
|
Virus Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS) detects cytosolic DNA during virus infection and induces an antiviral state. cGAS signals by synthesis of a second messenger, cyclic GMP-AMP (cGAMP), which activates stimulator of interferon genes (STING).
|
26229117 |
2015 |
|
Herpes Simplex Infections
|
0.030 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS) is a newly identified DNA sensor that recognizes foreign DNA, including the genome of herpes simplex virus 1 (HSV-1).
|
28100608 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS) is activated by ds-DNA binding to produce the secondary messenger 2',3'-cGAMP. cGAS is an important control point in the innate immune response; dysregulation of the cGAS pathway is linked to autoimmune diseases while targeted stimulation may be of benefit in immunoncology.
|
28940468 |
2017 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS) recognition of cytosolic DNA is critical for immune responses to pathogen replication, cellular stress, and cancer.
|
30007416 |
2018 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS) recognition of cytosolic DNA is critical for immune responses to pathogen replication, cellular stress, and cancer.
|
30007416 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway is a key regulator in innate immunity and has emerged as a promising drug target in cancer treatment, but the utility of this pathway in therapeutic development is complicated by its dichotomous roles in tumor development and immunity.
|
30790684 |
2019 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Cyclic GMP-AMP synthase (cGAS, cGAMP synthase) plays crucial roles in autoimmune disease, anti-tumor response, anti-senescence and anti-inflammatory response.
|
31276766 |
2019 |
|
AICARDI-GOUTIERES SYNDROME
|
0.030 |
Biomarker
|
disease |
BEFREE |
A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus.
|
27863149 |
2017 |
|
Lupus Vulgaris
|
0.010 |
Biomarker
|
disease |
BEFREE |
A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus.
|
27863149 |
2017 |
|
Lupus Erythematosus, Discoid
|
0.010 |
Biomarker
|
disease |
BEFREE |
A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus.
|
27863149 |
2017 |
|
Lupus Erythematosus
|
0.010 |
Biomarker
|
disease |
BEFREE |
A recently discovered DNA-activated type I IFN pathway, cyclic GMP-AMP synthase (cGAS), has been linked to Aicardi-Goutières syndrome and mouse models of lupus.
|
27863149 |
2017 |
|
Myocardial Infarction
|
0.020 |
Biomarker
|
disease |
BEFREE |
Animals lacking cyclic GMP-AMP synthase display significantly improved early survival after myocardial infarction and diminished pathological remodeling, including ventricular rupture, enhanced angiogenesis, and preserved ventricular contractile function.
|
29437120 |
2018 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Biallelic mutations of three prime repair exonuclease 1 (TREX1) cause the lupus-like disease Aicardi-Goutières syndrome in which accumulation of a yet unknown endogenous DNA substrate of TREX1 triggers a cyclic GMP-AMP synthase-dependent type I IFN response and systemic autoimmunity.
|
28835460 |
2017 |
|
Kidney Failure, Acute
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Cisplatin induced mtDNA leakage into the cytosol-probably through BCL-2-like protein 4 (BAX) pores in the mitochondrial outer membrane-in tubules, with subsequent activation of the cGAS-STING pathway, thereby triggering inflammation and AKI progression, which is improved in STING-deficient mice.
|
31665638 |
2019 |
|
Blindness
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these data highlight an unexpected role of cGAS in responding to mobile-element transcripts, reveal cGAS-driven interferon signaling as a conduit for mitochondrial-damage-induced inflammasome activation, expand the immune-sensing repertoire of cGAS and caspase-4 to noninfectious human disease, and identify new potential targets for treatment of a major cause of blindness.
|
29176737 |
2018 |
|
Virus Diseases
|
0.050 |
Biomarker
|
group |
BEFREE |
Collectively, this work identifies long DNA as the molecular entity stimulating the cGAS pathway upon cytosolic DNA challenge such as viral infections.
|
28801534 |
2017 |
|
Bacterial Infections
|
0.010 |
Biomarker
|
group |
BEFREE |
Cyclic dinucleotides are second messengers in the cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) pathway, which plays an important role in recognizing tumor cells and viral or bacterial infections.
|
31715099 |
2019 |
|
Autoinflammatory disorder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
DNA is strictly compartmentalized within the nucleus to prevent autoimmunity; despite this, cyclic GMP-AMP synthase (cGAS), a cytosolic sensor of double-stranded DNA, is activated in autoinflammatory disorders and by DNA damage.
|
28738408 |
2017 |
|
Autoimmune Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Dysregulated activation of the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway by self-DNA contributes to interferonopathy and promotes autoimmune diseases.
|
28771599 |
2017 |
|
Lupus Erythematosus, Systemic
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Expression of cGAS in peripheral blood mononuclear cells (PBMCs) was significantly higher in SLE patients than in normal controls (n = 51 and n = 20 respectively; P < 0.01).
|
27863149 |
2017 |
|
Autoimmune Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, EGCG-mediated inhibition of G3BP1 provides a potential treatment for cGAS-related autoimmune diseases.
|
30510222 |
2019 |
|
Autoinflammatory disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Given its role in the innate immune response, cGAS is a promising therapeutic target for autoinflammatory disease.
|
28934246 |
2017 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we show that cytoplasmic chromatin activates the innate immunity cytosolic DNA-sensing cGAS-STING (cyclic GMP-AMP synthase linked to stimulator of interferon genes) pathway, leading both to short-term inflammation to restrain activated oncogenes and to chronic inflammation that associates with tissue destruction and cancer.
|
28976970 |
2017 |